日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

NKp46 enhances type 1 innate lymphoid cell proliferation and function and anti-acute myeloid leukemia activity

NKp46 可增强 1 型固有淋巴细胞的增殖和功能以及抗急性髓系白血病活性。

Rui Ma # ,Zhenlong Li # ,Hejun Tang # ,Xiaojin Wu # ,Lei Tian ,Zahir Shah ,Ningyuan Liu ,Tasha Barr ,Jianying Zhang ,Sean Wang ,Srividya Swaminathan ,Guido Marcucci ,Yong Peng ,Michael A Caligiuri ,Jianhua Yu

Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death

通过诱导颗粒酶B介导的肿瘤细胞死亡,将人类2型固有淋巴细胞应用于治疗。

Zhenlong Li ,Rui Ma ,Hejun Tang ,Jiamin Guo ,Zahir Shah ,Jianying Zhang ,Ningyuan Liu ,Shuai Cao ,Guido Marcucci ,David Artis ,Michael A Caligiuri ,Jianhua Yu

Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer

人源抗PSCA CAR巨噬细胞对胰腺癌具有强大的抗肿瘤活性

Zahir Shah ,Lei Tian ,Zhixin Li ,Lewei Jin ,Jianying Zhang ,Zhenlong Li ,Tasha Barr ,Hejun Tang ,Mingye Feng ,Michael A Caligiuri ,Jianhua Yu

Isolation, expansion, and adoptive transfer of human ILC2s for the treatment of mice bearing liquid and solid tumors

分离、扩增和过继转移人ILC2细胞用于治疗患有血液肿瘤和实体瘤的小鼠

Zhenlong Li ,Rui Ma ,Hejun Tang ,Michael A Caligiuri ,Jianhua Yu

Human ILC1s target leukemia stem cells and control development of AML

人类ILC1靶向白血病干细胞并控制AML的发展

Michael Caligiuri, Zhenlong Li, Rui Ma, Hejun Tang, Jianying Zhang, Guido Marcucci, Jianhua Yu